Randomized trial of HPV4 vaccine assessing the response to HPV4 vaccine in two schedules among Peruvian female sex workers

Vaccine

Volumn 30, Issue 13, 2012, Pages 2309-2314

  Brown, Brandon ^a   Blas, Magaly ^b,c   Cabral, Alejandra ^a   Carcamo, Cesar ^c   Gravitt, Patti ^a,d   Halsey, Neal ^a  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^b NGO Via Libre ^*  (Peru)

^c UNIVERSIDAD PERUANA CAYETANO HEREDIA   (Peru)

^d PERDANA UNIVERSITY   (Malaysia)

Author keywords

Adherence; Female sex workers; HPV vaccine; Human papillomavirus; Immune response; Peru

Indexed keywords

VIRUS ANTIBODY; VIRUS DNA; WART VIRUS VACCINE;

ABSENCE OF SIDE EFFECTS; ADULT; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CANCER IMMUNIZATION; CONDYLOMA ACUMINATUM; CONTROLLED STUDY; DRUG RESPONSE; DRUG WITHDRAWAL; FEMALE; GROUPS BY AGE; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 11; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 6; MAJOR CLINICAL STUDY; PERU; PRIORITY JOURNAL; PROSTITUTION; RANDOMIZED CONTROLLED TRIAL; SEXUAL BEHAVIOR; UTERINE CERVIX CANCER; VIRUS IMMUNITY;

ADOLESCENT; ADULT; ALPHAPAPILLOMAVIRUS; ANTIBODIES, VIRAL; CERVIX UTERI; FEMALE; GAMMAPAPILLOMAVIRUS; HUMANS; IMMUNIZATION SCHEDULE; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; PERU; SEX WORKERS; TREATMENT OUTCOME; VACCINATION; YOUNG ADULT;

EID: 84857785393     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2012.01.058     Document Type: Article

References (24)

1. IARC. Monographs on the evaluation of carcinogenic risks to humans: human papillomaviruses. Lyon: International Agency for Research on Cancer: vol. 90; 2007 15-22 February.
2. Villa L.L., Ault K.A., Giuliano A.R., Costa R.L., Petta C.A., Andrade R.P., et al. Immunologic responses following administration of a vaccine targeting human papillomavirus types 6, 11, 16, and 18. Vaccine 2006, 24:5571-5583.
3. Villa L.L., Costa R.L., Petta C.A., Andrade R.P., Paavonen J., Iversen O.E., et al. High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up. Br J Cancer 2006, 95:1459-1466.
4. Calhoun B. Feasibility of a community-based voluntary HIV counseling and testing program in commercial sex venues in Lima, Peru. Third annual poster presentation at Puget Sound partners for global health lecture 2005.
5. Mak R., Van Renterghem L., Van Renterghem L., Cuvelier C. Cervical smears and human papillomavirus typing in sex workers. Sex Transm Infect 2007, 80:118-120.
6. Donmez H., Menevse S., Guner H., Menevse A. Detection and typing of human papillomavirus DNAs by restriction endonuclease mapping of the PCR products. Isr J Med Sci 1997, 33:789-793.
7. Volkow P., Rubi S., Lizano M., Carrillo A., Vilar-Compte D., Garcia-Carranca A., et al. High prevalence of oncogenic human papillomavirus in the genital tract of women with human immunodeficiency virus. Gynecol Oncol 2001, 82:27-31.
8. Marais D., Carrara H., Kay P., Ramjee G., Allan B., Williamson A.L. The impact of the use of COL-1492, a nonoxynol-9 vaginal gel, on the presence of cervical human papillomavirus in female sex workers. Virus Res 2006, 121:220-222.
9. Juárez-Figueroa L.A., Wheeler C.M., Uribe-Salas F.J., Conde-Glez C.J., Zampilpa-Mejía L.G., García-Cisneros S., et al. Human papillomavirus: a highly prevalent sexually transmitted disease agent among female sex workers from Mexico City. Sex Transm Dis 2001, 28:125-130.
10. Touze A., de Sanjose S., Coursaget P., Almirall M.R., Palacio V., Meijer C.J., et al. Prevalence of anti-human papillomavirus type 16, 18, 31, and 58 virus-like particles in women in the general population and in prostitutes. J Clin Microbiol 2001, 39:4344-4348.
11. de Sanjosé S., Diaz M., Castellsagué X., Clifford G., Bruni L., Muñoz N., et al. Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: a meta-analysis. Lancet Infect Dis 2007, 7:453-459.
12. Ferlay J., Bray F., Pisani P., Parkin D.M. Globocan 2002: cancer incidence, mortality, and prevalence worldwide. IARC 2004.
13. Brown B., Carcamo C., Blas M.M., Valderrama M., Halsey N. Peruvian FSWs: understanding HPV and barriers to vaccination. Vaccine 2010, 28(49):7743-7747.
14. Munoz N., Manalastas R., Pitisuttithum P., Tresukosol D., Monsonego J., Ault K., et al. Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24-45 years: a randomised, double-blind trial. Lancet 2009, 373:1949-1957.
15. Opalka D., Lachman C.E., MacMullen S.A., Jansen K.U., Smith J.F., Chirmule N., et al. Simultaneous quantitation of antibodies to neutralizing epitopes on virus-like particles for human papillomavirus types 6, 11, 16, and 18 by a multiplexed luminex assay. Clin Diagn Lab Immunol 2003, 10:108-115.
16. Dias D., Van Doren J., Schlottmann S., Kelly S., Puchalski D., Ruiz W., et al. Optimization and validation of a multiplexed luminex assay to quantify antibodies to neutralizing epitopes on human papillomaviruses 6, 11, 16, and 18. Clin Diagn Lab Immunol 2005, 12:959-969.
17. Schwarz T.F., Spaczynski M., Schneider A., Wysocki J., Galaj A., Perona P., et al. Immunogenicity and tolerability of an HPV-16/18 AS04-adjuvanted prophylactic cervical cancer vaccine in women aged 15-55 years. Vaccine 2009, 27:581-587.
18. Olsson S.E., Kjaer S.K., Sigurdsson K., Iversen O.E., Hernandez-Avila M., Wheeler C.M., et al. Evaluation of quadrivalent HPV6/11/16/18 vaccine efficacy against cervical and anogenital disease in subjects with serological evidence of prior vaccine type HPV infection. Hum Vaccines 2009, 5(10):696-704.
19. Halsey N.A., Moulton L.H., O'Donovan J.C., Walcher J.R., Thoms M.L., Margolis H.S., et al. Hepatitis B vaccine administered to children and adolescents at yearly intervals. Pediatrics 1999, 103:1243-1247.
20. Wouters K., Leuridan E., Van Herck K., Van Ardenne N., Roelofs I., Mak R., et al. Compliance and immunogenicity of two hepatitis B vaccination schedules in sex workers in Belgium. Vaccine 2007, 25:1893-1900.
21. Zimmerman R.K., Nowalk M.P., Lin C.J., Fox D.E., Ko F.S., Wettick E., et al. Randomized trial of an alternate human papillomavirus vaccine administration schedule in college-aged women. J Womens Health (Larchmt) 2010, 19(8):1441-1447.
22. Neuzil K.M., Canh do G., Thiem V.D., Janmohamed A., Huong V.M., Tang Y., et al. Immunogenicity and reactogenicity of alternative schedules of HPV vaccine in Vietnam: a cluster randomized noninferiority trial. JAMA 2011, 305(14):1424-1431.
23. Moscicki A.B., Hills N., Shiboski S., Powell K., Jay N., Hanson E., et al. Risks for incident human papillomavirus infection and low-grade squamous intraepithelial lesion development in young females. JAMA 2001, 285:2995-3002.
24. Vandepitte J., Lyerla R., Dallabetta G., Crabbe F., Alary M., Buve A. Estimates of the number of female sex workers in different regions of the world. Sex Transm Infect 2006, 82(Suppl. 3):iii18-iii25.